Allergan signs $3.34bn neurology deal with Heptares; partnership terminated
Executive Summary
On the heels of its recent break-up with Pfizer, Allergan PLC partnered with Sosei Group Corp.'s Heptares Therapeutics Ltd. to develop selective small-molecule muscarinic receptor agonists from Heptares' pipeline for Alzheimer's disease and related neurological diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice